Viking Therapeutics ( VKTX 1.92%) stock is soaring. Two years ago, the share price hovered just above $2. Today, shares trade ...

Will Viking have an approved GLP-1 drug in five years? The big question surrounding Viking Therapeutics today centers around ...

Wells Fargo released its annual biopharma M&A screen this week, including weight loss drug developer Viking Therapeutics ...

Viking Therapeutics (NASDAQ: VKTX), a clinical-stage company focused on developing novel therapeutics for metabolic and ...

Hope for a weight-loss drug that’s better than Ozempic and Wegovy has sent Viking Therapeutics Inc. shares skyrocketing. But ...

Viking Therapeutics, a clinical-stage company focused on metabolic and endocrine disorders, is primed for acquisition due to its robust pipeline and potential as a market disruptor. The company's ...

Investing in clinical-stage pharmaceutical companies comes with a lot of risk, but also a lot of potential upside. When such a company delivers a successful product that passes regulatory muster ...

Shares of Viking Therapeutics (NASDAQ:VKTX) have surged in the last 12 months, driven by the success of its obesity candidate, the subcutaneously administered VK2735. VK2735’s efficacy ...

Viking Therapeutics's VKTX short percent of float has risen 17.0% since its last report. The company recently reported that ...

Viking Therapeutics (NASDAQ: VKTX) isn't a household name, but if its plans to commercialize a powerful anti-obesity medicine come to fruition, it may well become one. Though it has yet to ...

Adagio Therapeutics Stock Price latest news, photos, videos, breaking news, special reports, blogs, and updates from Business ...